#ACRbest Peter Merkel as Distinguished Investigator said Data are good. Need data to develop questions, understand #vasculitis Hx of #vasculitis - great minds & drugs - now challenged by funding and comparators Session 15W127 #ACR23 @RheumNow @ACRheum https://t.co/5leIeLWZ6O

#ACR23 Abstr#2575 Do guidelines work? Data from UK cohort (N=290) re: utility of the International Guideline for IIM-assoc cancer screening detected 17 cases; most in high risk group & none in low risk. Need larger size, cases, screening timepoint & economic analysis @RheumNow https://t.co/G2bmmQbSox

Systematic review and meta-analysis of efficacy and and safety or therapies in Adult Onset Still's Disease and sJIA IL-1i and IL-6i - highest evidence for treatment Early (<3 months) intervention = higher rate of dz inactivity @RheumNow #ACR23 Abs#2569 https://t.co/XzzwbLFpo7

Tommasi et al. MTX (vs SSZ) lowers BP in RA in RCT. At 6 months, significant reduction in SBP (mean difference -4.0±10.8 mmHg, p=0.038), MAP (mean difference -4.3±17.9 mmHg, p=0.023). Abstr#2151 #ACR23 @RheumNow https://t.co/wAX3dCztxH https://t.co/mPG5TdeHTu

#vasculitis clinical trials are accelerating. Need the right time - early studies have lessons learned re feasibility and design/endpoints #ACR23 @RheumNow @ACRheum Great lecture - P Merkel 15W127 great graphs of vasculitis developments https://t.co/YRdPiaflxY

New MoA in RA 🚨 Dual inhibition BAFF/BLys Telalicept MTX IR pts Ph3 vs. PBO ACR20 60 vs. 27% ACR50 21 vs. 6% DAS28<3.2 15 vs. 5% Less Rx prog Safety similar infection rates @RheumNow #ACR23 ABSTL20 https://t.co/WHysLSKyo0

Serrano-Combarro et al. JAKi in RA-ILD. 73 patients on JAKi (74% Bari). Many had prev received abatacept/rituximab. HRCT improved/stable in 76%. Dyspnoea stable/improved in 95%. Abstr#2174 #ACR23 @RheumNow https://t.co/j6SiEzSRif

Long-term abatacept in UIP RA-ILD. 233 patients, median 22 month follow-up. Sustained benefits to previous data. ABA was withdrawn in 50 patients (21.5%) (ILD worsening 20, joint worsening 15, serious infections 7, others 8) Abstr#2165 #ACR23 @RheumNow https://t.co/SinE4GgFRE https://t.co/M1Nnce58OE

Knee OA, to inject or not to inject: the great debate 📣 A thread👇🏼👇🏼👇🏼 Maglette Klotenburg argues in favor, with moderation IA GC improves pain Repetitive injections can be harmful @RheumNow #ACR23 https://t.co/3p4UVLngpx

#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest https://t.co/Rj1k1z0Tsz

In case you missed it! AR882-selective oral URAT1i added to #allopurinol rapidly improves/dissolve #tophi. Given with #colchicine, #placebo 3/4 flared vs <1/2 w drug. My critique is why not optimize allopurinol dose - only 300 mg, no fuboxastat L15 #ACR23 @RheumNow @ACRheum https://t.co/NZWLpWXT51

Window of opportunity for abatacept in RA-ILD. Early treated patients (<6 months vs >2 years) appear to do better in terms of FVC. Abstr#2173 #ACR23 @RheumNow https://t.co/14IsA1KbAk https://t.co/ZbZEwzaOu0